Serum and CSF Biomarkers Predict Active Early Cognitive Decline Rather Than Established Cognitive Impairment at the Moment of RRMS Diagnosis.
RRMS
amyloid
cognitive decline
cognitive impairment
multiple sclerosis
neurofilaments
predictive biomarkers
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Oct 2022
23 Oct 2022
Historique:
received:
16
07
2022
revised:
19
10
2022
accepted:
20
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
(1) Background: Cognitive impairment (CI) begins early in the evolution of multiple sclerosis (MS) but may only become obvious in the later stages of the disease. Little data is available regarding predictive biomarkers for early, active cognitive decline in relapse remitting MS (RRMS) patients. (2) Methods: 50 RRMS patients in the first 6 months following diagnosis were included. The minimum follow-up was one year. Biomarker samples were collected at baseline, 3-, 6- and 12-month follow-up. Cognitive performance was assessed at baseline and 12-month follow-up; (3) Results: Statistically significant differences were found for patients undergoing active cognitive decline for sNfL z-scores at baseline and 3 months, CSF NfL baseline values, CSF Aβ42 and the Bremso score as well. The logistic regression model based on these 5 variables was statistically significant, χ2(4) = 22.335, p < 0.0001, R2 = 0.671, with a sensitivity of 57.1%, specificity of 97.4%, a positive predictive value of 80% and a negative predictive value of 92.6%. (4) Conclusions: Our study shows that serum biomarkers (adjusted sNfL z-scores at baseline and 3 months) and CSF biomarkers (CSF NfL baseline values, CSF Aβ42), combined with a clinical score (BREMSO), can accurately predict an early cognitive decline for RRMS patients at the moment of diagnosis.
Identifiants
pubmed: 36359416
pii: diagnostics12112571
doi: 10.3390/diagnostics12112571
pmc: PMC9689215
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Neurol. 2006 Aug;253(8):1002-10
pubmed: 16609812
J Ophthalmol. 2016;2016:8503859
pubmed: 27840739
Actas Esp Psiquiatr. 2015 Sep;43(5):187-93
pubmed: 26320897
Mol Psychiatry. 2015 Aug;20(8):986-94
pubmed: 25869803
PLoS One. 2016 Sep 06;11(9):e0162202
pubmed: 27598262
Noro Psikiyatr Ars. 2021 Aug 26;58(3):176-183
pubmed: 34526838
Eur J Neurol. 2015 Jun;22(6):981-9
pubmed: 25808578
Medicina (Kaunas). 2022 Mar 03;58(3):
pubmed: 35334554
Mult Scler. 2019 Aug;25(9):1223-1231
pubmed: 30084711
Lancet Neurol. 2012 Dec;11(12):1082-92
pubmed: 23153407
J Neurol. 2022 Jun;269(6):3249-3257
pubmed: 35088141
J Neurol. 2011 Sep;258(9):1603-8
pubmed: 21384163
Arch Gen Psychiatry. 2012 Jan;69(1):98-106
pubmed: 22213792
Arch Neurol. 1999 Jun;56(6):673-80
pubmed: 10369305
Acta Neurol Scand Suppl. 2006;183:48-50
pubmed: 16637929
Lancet Neurol. 2008 Sep;7(9):841-51
pubmed: 18703006
Neurol Sci. 2010 Nov;31(Suppl 2):S211-4
pubmed: 20640466
Mult Scler Relat Disord. 2017 Oct;17:57-62
pubmed: 29055476
Lancet Neurol. 2022 Mar;21(3):246-257
pubmed: 35182510
Front Neurol. 2021 Jul 13;12:678735
pubmed: 34326806
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 31;8(6):
pubmed: 34465616
J Int Med Res. 2019 May;47(5):2187-2198
pubmed: 30982375
Mult Scler. 2015 Dec;21(14):1761-70
pubmed: 25698172
Rev Neurosci. 2017 Nov 27;28(8):845-860
pubmed: 28787275
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Clin Neurol. 2021 Jan;17(1):113-120
pubmed: 33480206
Peptides. 2002 Jul;23(7):1205-14
pubmed: 12128078
Eur J Neurol. 2016 May;23(5):898-905
pubmed: 26872061
Clin Neuropsychol. 2015;29(6):824-35
pubmed: 26373627
Nat Med. 1998 Jul;4(7):832-4
pubmed: 9662376
Mult Scler Relat Disord. 2016 Nov;10:116-122
pubmed: 27919477
J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):469-75
pubmed: 15774430
Clin Ophthalmol. 2020 Oct 02;14:2995-3000
pubmed: 33061285
Front Neurosci. 2021 Apr 06;15:642384
pubmed: 33889068
Curr Pharm Des. 2017;23(5):693-730
pubmed: 27981909
J Neural Transm (Vienna). 2012 Jul;119(7):799-804
pubmed: 22460296
J Neuroinflammation. 2019 Dec 23;16(1):272
pubmed: 31870389
CNS Spectr. 2019 Feb;24(1):22-29
pubmed: 30468135
Eur J Neurol. 2021 Aug;28(8):2533-2542
pubmed: 33786942
Clin Chim Acta. 2015 Sep 20;449:23-30
pubmed: 25659291
BMC Neurol. 2018 May 11;18(1):67
pubmed: 29751782
Neural Regen Res. 2021 Jan;16(1):36-42
pubmed: 32788445
J Neurol. 2008 Oct;255(10):1555-60
pubmed: 18825432
Neurol Sci. 2021 Dec;42(12):5183-5193
pubmed: 33796947
Nat Rev Neurosci. 2018 Oct;19(10):599-609
pubmed: 30158590
CNS Drugs. 2018 Feb;32(2):117-133
pubmed: 29417493
Int Rev Psychiatry. 2017 Oct;29(5):463-472
pubmed: 28681616
Front Neurol. 2019 Jan 23;9:1172
pubmed: 30728801
Cogn Behav Neurol. 2019 Sep;32(3):201-207
pubmed: 31517704
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14
pubmed: 23431079
Brain. 2021 Nov 29;144(10):2954-2963
pubmed: 34180982
Eur J Neurol. 2018 Sep;25(9):1189-1191
pubmed: 29797629
Neuropsychopharmacology. 2011 Feb;36(3):559-68
pubmed: 20944553
Arq Neuropsiquiatr. 2016 Dec;74(12):974-981
pubmed: 27991994
Crit Rev Clin Lab Sci. 2022 Sep;59(6):391-404
pubmed: 35277112
Front Immunol. 2020 Aug 20;11:1799
pubmed: 32973754
Brain Pathol. 2015 Jan;25(1):79-98
pubmed: 25521179